Essential thrombocythemia

Essential Thrombocythemia Market to Witness Upsurge in Growth by 2032, Predicts DelveInsight | Key Companies to Look Out - Imago BioSciences, Incyte, Karyopharm, Novartis, PharmaEssentia, Celgene, Kartos, Sierra Oncology

Retrieved on: 
Wednesday, August 30, 2023
GSK plc, Disease, Headache, Essential thrombocythemia, Bleeding, Prevalence, Conditional sentence, Hydroxycarbamide, Bone marrow, Genetic testing, Platelet, Petechia, Aspirin, Common, LAS, Bruise, Dizziness, Spleen, Novartis, Patient, Risk, Physiology, Plateletpheresis, Blood, MMB, CTI, Thrombocythemia, United Kingdom, Abdomen, Diagnosis, Oncology, Haematopoietic system, Skin, Medical device, Medical imaging, Pacritinib, Momelotinib, Ropeginterferon alfa-2b

LAS VEGAS, Aug. 30, 2023 /PRNewswire/ -- DelveInsight's Essential Thrombocythemia Market Insights report includes a comprehensive understanding of current treatment practices, essential thrombocythemia emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Points: 
  • These factors along with the expected launch of emerging therapies will boost the essential thrombocythemia market in the forecasted period.
  • As per DelveInsight analysts, total prevalent population of essential thrombocythemia in the 7MM was 240K in 2020.
  • Estimates observed that the age-group 60-80 years accounted for highest cases of essential thrombocythemia in the United States.
  • To know more about essential thrombocythemia treatment, visit @ Essential Thrombocythemia Treatment Drugs

Essential Thrombocythemia Market to Witness Upsurge in Growth by 2032, Predicts DelveInsight | Key Companies to Look Out - Imago BioSciences, Incyte, Karyopharm, Novartis, PharmaEssentia, Celgene, Kartos, Sierra Oncology

Retrieved on: 
Wednesday, August 30, 2023
GSK plc, Disease, Headache, Essential thrombocythemia, Bleeding, Prevalence, Conditional sentence, Hydroxycarbamide, Bone marrow, Genetic testing, Platelet, Petechia, Aspirin, Common, LAS, Bruise, Dizziness, Spleen, Novartis, Patient, Risk, Physiology, Plateletpheresis, Blood, MMB, CTI, Thrombocythemia, United Kingdom, Abdomen, Diagnosis, Oncology, Haematopoietic system, Skin, Medical device, Medical imaging, Pacritinib, Momelotinib, Ropeginterferon alfa-2b

LAS VEGAS, Aug. 30, 2023 /PRNewswire/ -- DelveInsight's Essential Thrombocythemia Market Insights report includes a comprehensive understanding of current treatment practices, essential thrombocythemia emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Points: 
  • These factors along with the expected launch of emerging therapies will boost the essential thrombocythemia market in the forecasted period.
  • As per DelveInsight analysts, total prevalent population of essential thrombocythemia in the 7MM was 240K in 2020.
  • Estimates observed that the age-group 60-80 years accounted for highest cases of essential thrombocythemia in the United States.
  • To know more about essential thrombocythemia treatment, visit @ Essential Thrombocythemia Treatment Drugs

Imago BioSciences Reports Third Quarter 2022 Financial Results and Provides Recent Business Updates

Retrieved on: 
Wednesday, November 9, 2022
Short-term investment fund, Blood, Sale, G&A, Company, Pancreatic serous cystadenoma, Treatment, Administration, MF, Review, Forward-looking statement, PV, Food, Society, Bone marrow, Genomics, Compliance, Cancer, Patient, COVID-19, Private Securities Litigation Reform Act, Regulation of tobacco by the U.S. Food and Drug Administration, Essential thrombocythemia, R, Polycythemia vera, EMA, Poster, ET, Growth, Hematology, FDA, GLOBE, Investment, Pandemic, Ruxolitinib, Good manufacturing practice, Annual report, Failure, Fast Track, Safety, LSD1, Priority, Research and development, European Medicines Agency, Pharmaceutical industry, Imago

REDWOOD CITY, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.

Key Points: 
  • Imago continues to make progress in the clinical development of Bomedemstat for the treatment of MPNs including essential thrombocythemia (ET), polycythemia vera (PV) and myelofibrosis (MF).
  • Cash, Cash Equivalents, and Short-Term Investments: As of September30, 2022, Imago had cash, cash equivalents, and short-term investments of $178.4 million compared to $217.4 million as of December31, 2021.
  • Net Loss: Net loss for the quarter ended September30, 2022 was $16.8 million, compared to $11.7 million for the same period in 2021.
  • Imago is focused on improving the quality and length of life for patients with cancer and bone marrow diseases.

Review of SURPASS-ET Trial Evaluating Ropeginterferon Alfa-2b-njft for Essential Thrombocythemia (ET) Published in Future Oncology

Retrieved on: 
Monday, August 8, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Infectious Diseases, Clinical Trials, FDA, Woman, Myeloproliferative neoplasm, Disorder, Risk, Hematology, Interferon, Interferon alfa-2b, Legislation, JAK2, European Medicines Agency, PV, Private Securities Litigation Reform Act, Medical Affairs Bureau, ELN, Â, Disease, Bleeding, Essential thrombocythemia, Identity provider (SAML), Research, ET, Department, Blood, Cancer, MPN, Lymphatic system, Man, Patient, Quality of life, Twitter, Pancreatic serous cystadenoma, Therapy, Biotechnology, Safety, Polycythemia vera, Thrombosis, TSS, Polycythemia, Physician, University, Ruxolitinib, LinkedIn, MD Anderson Cancer Center, EMA, Future Oncology, Pharmacokinetics, Medical imaging, Pharmaceutical industry

Ropeginterferon alfa-2b-njft is a unique monopegylated, long-acting interferon that was recently approved to treat adults with polycythemia vera (PV), another type of MPN.

Key Points: 
  • Ropeginterferon alfa-2b-njft is a unique monopegylated, long-acting interferon that was recently approved to treat adults with polycythemia vera (PV), another type of MPN.
  • Given the well-established safety and efficacy profile demonstrated in prior studies, the treatment may represent a useful alternative to approved options for ET.
  • Physicians treating people with MPNs have lacked effective, durable therapeutics that are designed specifically for these cancers.
  • The global phase 3, randomized, open-label, multicenter SURPASS-ET (NCT04285086) trial is evaluating the safety, efficacy, tolerability, and pharmacokinetics of ropeginterferon alfa-2b-njft compared to anagrelide as second-line therapy in high-risk ET.

UAE Wearable Medical Devices Market Report 2022: Ongoing Digitization Trends in the Healthcare Industry and the Launch of Novel Wearable Medical Devices Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 20, 2022
Technology, Health, Medical Devices, Wearables, Mobile Technology, Diabetes, Diagnosis, Investment, Awareness, Essential thrombocythemia, Mortality, Temperature, Activity, Research, Application, Degenerative disease, Intention, Site, Adoption, Health, Market share, Sleep, Growth, Obesity, Prevalence, Medical device, Pharmaceutical industry

UAE wearable medical devices market is expected to grow at a formidable rate during the forecast period.

Key Points: 
  • UAE wearable medical devices market is expected to grow at a formidable rate during the forecast period.
  • Ongoing digitization trends in the healthcare industry and the launch of novel wearable medical devices are also some of the factors contributing to the growth of the UAE wearable medical devices market.
  • Rising investments from market players in research & development activities for better healthcare management and the growing inclination of consumers towards purchasing wearable medical devices for chronic disease management, elderly care, and fitness management are supporting the UAE wearable medical devices market growth.
  • In this report, UAE wearable medical devices market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
    UAE Wearable Medical Devices Market, By Type:
    UAE Wearable Medical Devices Market, By Products:

Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at EHA 2022

Retrieved on: 
Friday, June 10, 2022
Congress, Ruxolitinib, Plasma, Dysgeusia, Sale, COVID-19, Omicron, European Medicines Agency, Cancer, Șaeș, MPL, ELN, Lymphatic system, Pancreatic serous cystadenoma, Ageing, CEO, Bleeding, Lists of disasters, ET, Arthralgia, MF, Blood, Trial of the century, Bone marrow, Essential thrombocythemia, AES, EMA, Priority, Annual report, Webcast, TSS, Patient, Fast Track, JAK2, Compliance, EHA, Mutation, Private Securities Litigation Reform Act, Constipation, LSD1, Facebook, Society, Fatigue, ASH, LinkedIn, Platelet, MPN, FDA, Growth, GLOBE, Risk, Pandemic, Causality, SAN, CALR, Safety, Pharmaceutical industry, Residential care, Bottled water, Medical imaging, Imago

The data were presented in a poster session during the 30th European Hematology Association Annual Meeting and Congress (EHA) taking place 9-12 June 2022.

Key Points: 
  • The data were presented in a poster session during the 30th European Hematology Association Annual Meeting and Congress (EHA) taking place 9-12 June 2022.
  • Of the 31 patients with Total Symptom Score (TSS) data available at 24 weeks:
    58% (18/31) showed a decrease in TSS.
  • I am genuinely thrilled with the results of our ongoing Phase 2 clinical study of bomedemstat in essential thrombocythemia (ET) that continues to support the tremendous potential of our drug candidate.
  • Imago is evaluating Bomedemstat as a potentially disease-modifying therapy in two Phase 2 clinical trials for the treatment of essential thrombocythemia ( NCT04254978 ) and myelofibrosis ( NCT03136185 ).

Imago BioSciences to Host Virtual Investor Event

Retrieved on: 
Monday, June 6, 2022
Congress, Company, Facebook, LSD1, EMA, Safety, Priority, Ruxolitinib, LinkedIn, Pancreatic serous cystadenoma, Annual report, Webcast, Lists of disasters, ET, MF, Blood, Sale, 2021 Essex County Council election, Growth, Patient, Cancer, GLOBE, Private Securities Litigation Reform Act, Fast Track, COVID-19, Bone marrow, Pandemic, Compliance, EHA, European Medicines Agency, Essential thrombocythemia, Mobile phone, Pharmaceutical industry, Primary myelofibrosis, Imago

SOUTH , June 06, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago” or the “Company”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today announced that a virtual investor event will be hosted by the company’s management team following the company’s presentations at EHA in Vienna, Austria and virtually.

Key Points: 
  • The webcast will be available in the investor relations section on the Company's website for 90 days following the completion of the call.
  • Imago will present two posters at EHA reporting updated data from its Phase 2 studies of bomedemstat for the treatment of Essential Thrombocythemia and Myelofibrosis, respectively.
  • Imago is focused on improving the quality and length of life for patients with cancer and bone marrow diseases.
  • Imago is evaluating Bomedemstat as a potentially disease-modifying therapy in two Phase 2 clinical trials for the treatment of essential thrombocythemia ( NCT04254978 ) and myelofibrosis ( NCT03136185 ).

Imago BioSciences Reports Third Quarter 2021 Financial Results and Provides Recent Business Updates

Retrieved on: 
Wednesday, November 10, 2021
Society, Degenerative disease, Bone marrow, Cancer, Pancreatic serous cystadenoma, G&A, Private Securities Litigation Reform Act, SAN, R, ET, Cash, Pfizer, EMA, ASH, European Medicines Agency, Investment, Russell, MF, COVID-19, Treatment, Administration, Facebook, 2021 Essex County Council election, Priority, Exposition, Essential thrombocythemia, LSD1, GLOBE, Awareness, IPO, LinkedIn, Ministry of Education (Malaysia), Initial public offering, Ruxolitinib, Blood, Research and development, Patient, Orphan, Pharmaceutical industry, Security (finance)

(Imago) (Nasdaq: IMGO), a clinical-stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today reported financial results for the third quarter ended September 30, 2021 and highlighted recent corporate updates.

Key Points: 
  • (Imago) (Nasdaq: IMGO), a clinical-stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today reported financial results for the third quarter ended September 30, 2021 and highlighted recent corporate updates.
  • Russell 2000 Index Inclusion: In September 2021, Imago announced its inclusion in the Russell 2000 Index as part of the Index's quarterly IPO additions.
  • Cash and Cash Equivalents: As of September 30, 2021, Imago had cash, cash equivalents, restricted cash and short-term investments of $230.4 million.
  • Net Loss: Net loss for the quarter ended September 30, 2021 was $11.7 million compared to $4.3 million for the same period in 2020.

PharmaEssentia Announces Pipeline Presentation During Upcoming American Society of Hematology Annual Meeting

Retrieved on: 
Thursday, October 21, 2021
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Safety, Hydroxycarbamide, Woman, Medical Affairs Bureau, Biotechnology, Polycythemia, Blood, LinkedIn, Disease, Hematology, European Medicines Agency, ET, Essential thrombocythemia, Twitter, File, EMA, Patient, Private Securities Litigation Reform Act, BLA, Pancreatic serous cystadenoma, FDA, MPN, Ropeginterferon alfa-2b, Food, Review, Risk, Time, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, PV, JAK2, MPL, Man, Myeloproliferative neoplasm, Pharmacokinetics, Solution, Ruxolitinib, Legislation, Society, ELN, Pharmaceutical industry, Medical imaging, Ropeginterferon alfa-2b, Essential Thrombocythemia, PharmaEssentia, ROPEGINTERFERON ALFA-2B, ESSENTIAL THROMBOCYTHEMIA, PHARMAESSENTIA

PharmaEssentia Corporation (TPEx: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced plans to present new updates on its pipeline during the 63rd American Society of Hematology Annual Meeting , December 11-14, 2021.

Key Points: 
  • PharmaEssentia Corporation (TPEx: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced plans to present new updates on its pipeline during the 63rd American Society of Hematology Annual Meeting , December 11-14, 2021.
  • PharmaEssentia continues to enroll participants in the trial at sites throughout the United States and Asia, and has now expanded with new sites in Canada.
  • We are pleased to partner with these renowned MPN specialists to participate in this important study.
  • PharmaEssentia continues to build momentum with its pipeline to deliver new solutions in MPNs.

Imago BioSciences’ Bomedemstat Demonstrates Continued Encouraging Clinical Activity in Phase 2 Data for Treatment of Essential Thrombocythemia and Myelofibrosis at EHA 2021 Virtual Congress

Retrieved on: 
Friday, June 11, 2021
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Thrombocythemia, Essential thrombocythemia, Primary myelofibrosis, Clinical medicine, Medicine, Health

The data were presented in two e-poster presentations during the 26th European Hematology Association Virtual Congress (EHA 2021), taking place June 9-17, 2021.

Key Points: 
  • The data were presented in two e-poster presentations during the 26th European Hematology Association Virtual Congress (EHA 2021), taking place June 9-17, 2021.
  • The presented data show that bomedemstat was generally well-tolerated by patients with ET and demonstrated encouraging clinical activity as a monotherapy, showing symptomatic improvement in patients with significant MPN symptoms.
  • These encouraging data show that bomedemstat was well-tolerated and has the potential to bring meaningful clinical benefits for patients with essential thrombocythemia, said Wan-Jen Hong, M.D., chief medical officer of Imago BioSciences.
  • Imago is evaluating Bomedemstat as a potentially disease-modifying therapy in two Phase 2 clinical trials for the treatment of essential thrombocythemia (ET) and myelofibrosis (MF).